King Wealth Management Group Has $74,000 Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

King Wealth Management Group increased its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 24.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,700 shares of the biotechnology company’s stock after purchasing an additional 2,700 shares during the period. King Wealth Management Group’s holdings in Aldeyra Therapeutics were worth $74,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. US Bancorp DE acquired a new position in shares of Aldeyra Therapeutics in the 3rd quarter worth approximately $30,000. SG Americas Securities LLC acquired a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $38,000. Diversified Trust Co acquired a new stake in Aldeyra Therapeutics during the 2nd quarter worth $41,000. Laidlaw Wealth Management LLC boosted its position in shares of Aldeyra Therapeutics by 32.6% during the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 4,150 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Aldeyra Therapeutics by 14.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock worth $72,000 after buying an additional 2,729 shares during the period. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Friday, August 9th.

Aldeyra Therapeutics Trading Down 3.2 %

Shares of NASDAQ:ALDX opened at $4.27 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The business has a 50 day moving average of $5.53 and a 200-day moving average of $4.60. Aldeyra Therapeutics, Inc has a 12-month low of $2.43 and a 12-month high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.25). On average, equities analysts predict that Aldeyra Therapeutics, Inc will post -0.48 earnings per share for the current year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.